CION Ameerpet
Radiation Therapy · Modality & Technology
Intraoperative Radiotherapy (IORT) — One Dose During Surgery
Medically reviewed by Dr. Gangadhar Vajrala, Radiation Oncologist, MBBS · MD (Radiation Oncology) · MPH · Last reviewed August 2026
IORT delivers a single, targeted dose of radiation to the tumour bed in the operating theatre, immediately after the lump is removed and while you are still under anaesthesia. It adds roughly 20 to 40 minutes to the operation. For a narrow, low-risk group it can be the only radiation you need — for most people, it is not.
- One dose, given in theatre — the radiation is delivered once, before the wound is closed, so there is no separate radiation appointment on the day and no daily travel afterwards if you qualify.
- Eligibility is genuinely narrow — international guidance limits IORT to a small, low-risk group. Being told you are not a candidate is the usual answer, not a second-best one.
- Final pathology can change the plan — if the report after surgery shows involved margins, node involvement or higher-risk features, the standard external course is added on top.
- Availability in India is limited — IORT needs a dedicated device inside the theatre. CION does not own or operate radiotherapy equipment; your radiotherapy is delivered at an NABH-accredited partner centre while CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
How is IORT actually given?
IORT is given once, in the operating theatre. After the surgeon removes the tumour, an applicator is placed into the cavity it left behind, or a mobile accelerator is aimed at the exposed tumour bed. A single dose is delivered over roughly 20 to 40 minutes. The device comes out and the wound is closed.
You are asleep for all of it. There is no separate appointment, no mask, no daily positioning on a treatment couch. What changes is the length of your operation, not the number of hospital visits on the day.
- The lump is removed as planned. IORT is added to a breast-conserving operation. It does not replace the surgery and it is not an alternative to having the tumour taken out.
- The cavity is prepared. The surgeon draws the tissue lining the cavity together around the applicator, so the dose lands exactly where a recurrence would be most likely to start.
- One dose is delivered. Depending on the system, this is either low-energy X-rays from a spherical applicator sitting inside the cavity, or an electron beam aimed at the tumour bed from a mobile accelerator wheeled into theatre.
- Nearby tissue is shielded. Skin, ribs, lung and heart are protected by shields and by the beam falling away sharply over a short distance. Reduced exposure of neighbouring organs is one of the genuine attractions of the technique.
- The device is removed and the wound closed. Theatre time is extended by roughly 20 to 40 minutes. You wake up having had both the operation and the radiation.
- Pathology decides what happens next. The removed tissue goes to the laboratory. The final report on margins, lymph nodes, grade and receptors determines whether any further radiation is advised.
Your radiotherapy is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. CION does not own or operate radiotherapy equipment of any kind.
Did you know?
IORT was built around a simple observation: when breast cancer returns in the same breast, it most often comes back in or immediately beside the original tumour bed. That is the small volume IORT treats — and it is also the reason the technique can only be considered when the disease is confined and low-risk to begin with. Current as of August 2026.
The question marketing skips
Does IORT replace the full course of radiation?
Sometimes, but not usually — and you will not know for certain on the day of your operation. IORT is intended to be the only radiation for a carefully selected low-risk group. For everyone else it acts as an early boost, and the standard external course is still given afterwards.
The deciding document is the final pathology report, and it arrives days after the surgery is over. Your surgeon selects you for IORT using the pre-operative biopsy, imaging and clinical examination. The laboratory then examines the whole specimen, and it can find things the scans did not show.
If the report shows involved or close margins, cancer in the armpit lymph nodes, lymphovascular invasion, an extensive in-situ component or a higher grade than expected, guideline-based care adds the standard course on top of the dose already given. That is not a complication or a mistake. It is the built-in safety net of a risk-adapted approach.
ASTRO advises that anyone considering intraoperative partial breast irradiation should be counselled that the risk of the cancer returning in the same breast is higher than with whole-breast radiotherapy. NCCN and ESMO both list partial breast irradiation as an option for selected low-risk patients only, not as a general substitute.
Ask before you consent: "If my pathology comes back with anything unexpected, what is the plan, and what does that do to my cost and my timeline?" Agreeing to IORT is agreeing to a possibility of avoiding the daily course, not a certainty of it.
Stated plainly
Who is actually eligible for IORT?
Only a narrow, low-risk group. Guidance from ASTRO, ESMO and NCCN on partial breast irradiation points to women past about 50, with a single small invasive tumour, clear margins, no cancer in the armpit lymph nodes, hormone-receptor-positive lower-grade disease and no inherited high-risk gene. Miss one criterion and IORT is usually off the table as your only radiation.
Usually considered suitable
- Age around 50 or older — some protocols allow 45 and above, because younger age itself raises the risk of the cancer returning in the breast.
- A single invasive tumour, generally around 2 to 3 cm or smaller, with no second focus elsewhere in the breast.
- Clinically node-negative disease — no cancer detected in the armpit lymph nodes before surgery.
- Hormone-receptor-positive, HER2-negative, low or intermediate grade tumour biology.
- Clear surgical margins confirmed on the final pathology report.
- No lymphovascular invasion and no extensive in-situ component in the specimen.
- Breast-conserving surgery, not mastectomy, and no systemic treatment given before the operation.
Usually rules IORT out
- A known inherited high-risk gene such as BRCA1 or BRCA2, which raises the chance of new disease elsewhere in the same breast.
- Age under about 45, where guidelines are consistently more cautious about partial breast irradiation.
- More than one tumour in the breast, or widespread in-situ disease seen on imaging.
- Cancer found in the lymph nodes, or involved and close margins on the final report.
- Triple-negative or high-grade disease, where the pattern of recurrence risk is different.
- Radiation already given to the same breast in the past.
- Mastectomy rather than lumpectomy, where the tumour bed being treated no longer exists in the same form.
These are guidance ranges, not fixed rules, and they differ slightly between the low-energy X-ray and electron-beam approaches. Your own eligibility is decided by your surgical and radiation oncology team from your reports, not from a checklist on a website.
Side by side
IORT vs external partial breast radiation vs the standard whole-breast course
A starting framework to take into your own consultation. Every row is a question worth asking your radiation oncologist directly about your specific case.
| Factor | IORT (single dose in theatre) | External partial breast radiation | Whole-breast radiation (standard) |
|---|---|---|---|
| When it is given | During the operation, before the wound is closed | After surgery, once pathology is known | After surgery, once pathology is known |
| Number of visits for radiation | None — it happens inside the operation | Typically about 5 to 15 sessions over 1 to 3 weeks | Typically about 15 to 25 weekday sessions over 3 to 5 weeks |
| What is treated | The tumour bed only, from inside the cavity | The tumour bed plus a margin, aimed from outside | The whole breast, sometimes with a boost to the bed |
| Pathology known before the dose? | No — selection is based on pre-operative findings | Yes | Yes |
| Chance more radiation is added later | Real, and decided by the final report | Low, because the plan is made after pathology | Not applicable |
| Local recurrence risk versus whole-breast radiation | Higher — ASTRO advises explicit counselling on this | Comparable in appropriately selected patients per guidelines | The long-standing reference standard |
| Exposure of skin, heart and lung | Lowest of the three | Lower than whole-breast treatment | Highest of the three, though modern planning keeps doses low |
| Who it suits | A small, low-risk, node-negative group only | Selected low-risk patients, a wider group than IORT | The great majority of patients after breast-conserving surgery |
| Availability in India | Very limited — a small number of centres; not a routine option across Hyderabad | Available at many radiotherapy centres | Widely available |
| Travel burden | None beyond the operation itself | A short course of daily trips | Daily trips for several weeks |
| Cost pattern (indicative only, as of August 2026) | One high-cost episode; ask what happens to the price if the full course is added | Priced per session over a short course | Priced per session over a longer course |
| Delivered at | An NABH-accredited partner centre; CION coordinates your plan, your team and your care | ||
This table compares approaches in general terms. Which one applies to you depends on your tumour size, receptor status, node status, margins and age — ask your radiation oncologist how each row reads against your own pathology report.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer on whether IORT applies to you
A radiation oncologist can read your pathology and scan reports and tell you plainly whether a single intraoperative dose is realistic for your case, or whether the standard course is the right plan — free and confidential.
Read the promise carefully
What IORT marketing usually leaves out
IORT is one of the most over-promised techniques in cancer marketing. None of these points make it a bad option. They make it a narrower one than the headline suggests.
One dose
One dose is the plan, not the promise
The final pathology report can still add the standard course afterwards. Ask what proportion of that centre's IORT patients go on to need it.
Not a shortcut
It does not replace the operation
IORT is added to breast-conserving surgery. You still have an anaesthetic, an incision and a recovery. Only the radiation schedule changes.
The trade-off
Convenience is exchanged for a higher local recurrence risk
ASTRO asks that patients be counselled on this before choosing intraoperative partial breast irradiation. It is a reasonable trade only in genuinely low-risk disease.
Eligibility
Most people asking about it will not qualify
Node involvement, younger age, larger or multiple tumours, or a high-risk inherited gene each take IORT off the table on their own.
Availability
The device has to be in your theatre
IORT needs the equipment, a physicist and radiation-safety clearance in the operating room itself. Very few centres in India are set up for it.
Newer is not better
Recency says nothing about fit
The right technique is the one that matches your tumour biology, size, margins and node status. Launch date is not a clinical criterion.
The scenario worth planning for
What happens if the pathology report changes the plan?
Your team meets, usually as a multidisciplinary board, and reviews the full specimen report against the reason you were selected for IORT. If a higher-risk feature has appeared, the recommendation is generally to complete the standard external course, with the intraoperative dose then counted as the boost to the tumour bed.
Practically, that means the timeline you were given moves. Planning scans, marking and a course of daily weekday sessions are added, usually starting a few weeks after surgery once healing allows. It also means the cost you were quoted for IORT alone is no longer the whole cost.
Occasionally the report shows the margins were not clear, and a second operation to widen them is discussed before radiation is finalised. This is a recognised possibility with any breast-conserving surgery, not something unique to IORT.
None of this is failure. It is the system working as intended: an early dose given at the most likely site of recurrence, then the plan corrected once the laboratory has seen everything. What you should insist on is that the possibility is explained, costed and consented to before the operation, not discovered afterwards.
Bring these to your consult
Questions worth asking before you agree to IORT
These keep the conversation on your pathology rather than on the technology.
- On my pre-operative reports, do I actually meet the partial breast irradiation criteria? Ask which specific criteria you meet and which are borderline.
- What is the chance I will still need the full course afterwards? Ask for the centre's own experience, not a general figure.
- What exactly happens if my margins come back involved? Get the plan for that scenario in writing before you consent.
- Which IORT approach would be used, and is that device present in the theatre where I am being operated on?
- How does my age and receptor status affect the recommendation? Younger age and higher-risk biology both weigh against partial breast irradiation.
- What is the indicative cost, and what does it become if the standard course is added? Ask for both figures, dated, and check insurance or scheme cover.
You should not have to decode marketing claims alone
One consultation usually settles whether IORT is even on the table
Whether you have read about IORT online or heard it mentioned in a consult, a radiation oncologist can map your own tumour details against the eligibility criteria and tell you where you stand.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Intraoperative radiotherapy — your questions answered
How is intraoperative radiotherapy (IORT) given during breast surgery?
IORT is given once, inside the operating theatre, while you are still asleep. After the surgeon removes the tumour, a small applicator is placed into the cavity it left behind, or a mobile accelerator is aimed at the exposed tumour bed. A single dose is delivered over roughly 20 to 40 minutes, the device is taken out, and the wound is closed in the usual way. You do not feel it and you do not come back for it. Theatre time is extended, but there is no separate radiation appointment on the day.
Does IORT replace the full course of radiation?
Sometimes, but not usually, and you will not know for certain on the day of your operation. IORT is intended to be the only radiation for a carefully selected low-risk group. For everyone else it acts as an early boost, with the standard external course still given afterwards. The deciding factor is the final pathology report, which arrives days after surgery. If it shows involved or close margins, cancer in the lymph nodes, lymphovascular invasion or a higher grade than expected, guideline-based care adds the standard course. Agreeing to IORT is agreeing to a possibility, not a certainty.
Who is eligible for intraoperative radiotherapy?
Only a narrow, low-risk group. Guidance from ASTRO, ESMO and NCCN on partial breast irradiation points to women past about 50, with a single small invasive tumour, clear surgical margins, no cancer in the armpit lymph nodes, hormone-receptor-positive and lower-grade disease, and no inherited high-risk gene such as BRCA1 or BRCA2. Breast-conserving surgery rather than mastectomy is assumed. Miss any one of these and IORT is usually not offered as your only radiation. Being told you are not a candidate is the common outcome, not a lesser standard of care.
Is IORT available in India, and in Hyderabad?
Availability is limited. IORT needs a dedicated radiation device physically present in the operating theatre, plus a radiation oncologist, a medical physicist and radiation-safety clearance for that theatre. Only a small number of centres in India have set this up, and it is not a routine offering across Hyderabad. If IORT is not available where you are being treated, that is not a downgrade. Standard whole-breast or external partial-breast radiation remains the guideline-recommended approach for the overwhelming majority of patients. CION Cancer Clinics does not own or operate radiotherapy equipment of any kind.
Is IORT better than standard radiation because it is newer?
No. Newer describes when a technique arrived, not how well it fits your tumour. ASTRO advises that patients considering intraoperative partial breast irradiation should be counselled that the risk of the cancer returning in the same breast is higher than with whole-breast radiotherapy. That trade-off is accepted in exchange for a single dose and far less travel, and it is only reasonable when the disease is genuinely low-risk. The honest framing is convenience and reduced exposure of nearby tissue set against a higher local recurrence risk, judged case by case with your radiation oncologist.
Does IORT cost less than a full course of radiation?
Not necessarily, and any figure you are quoted is indicative only, as of August 2026. IORT compresses radiation into one dose, which removes weeks of daily travel, time off work and accommodation costs. Against that, the device, the extra theatre time and the staffing are charged as one high-cost episode, and if the final pathology adds the standard course afterwards you pay for both. Ask for a written estimate that states clearly what happens to the price if further radiation becomes necessary, and check your insurance or scheme cover before you decide.
This page explains intraoperative radiotherapy in general terms. It is not a substitute for guidance from your own surgical and radiation oncology team about your tumour, your pathology report and your treatment plan.